MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- STRIDES PHARMA SCIENCE
STRIDES PHARMA SCIENCE Share Price 
(PLLB)
Here is the latest stock price and chart of STRIDES PHARMA SCIENCE. For more details, see the STRIDES PHARMA SCIENCE company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Dec 12, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)463.30 | Open (Rs) 458.55 | High (Rs) 474.00 | Low (Rs) 453.95 |
| % Change1.07 | Volume 146,779 | Value (Rs) 68,005,316 | 52-Week H/L 855.20 / 334.10 |
| Live NSE Quotes | Dec 12, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)462.95 | Open (Rs) 459.50 | High (Rs) 473.65 | Low (Rs) 453.40 |
| % Change0.79 | Volume 1,672,463 | Value (Rs) 773,125,355 | 52-Week H/L 855.95 / 333.30 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 8.96 | P/E Ratio (x) 51.69 | Market Cap (Rs m) 27,635.85 | P/BV (x) 1.13 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
STRIDES PHARMA SCIENCE Share Price Today:
STRIDES PHARMA SCIENCE last traded price was up 1.1% to Rs 463.3 on the BSE. On the NSE, STRIDES PHARMA SCIENCE last traded price was up 0.8% to Rs 463.0. The total volume of shares traded was 1.8 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.9%. And the benchmark S&P BSE SENSEX was at 35,779.1 (up 1.8%).
Over the last 30 days, the STRIDES PHARMA SCIENCE share price is down 0.1%. And over the last one year, STRIDES PHARMA SCIENCE share price is down 42.2%.
|
| |
Today's Market
Indian Indices End on a Strong Note, US-China Trade Talks, and Top Cues in Focus Today(Pre-Open)
Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.
Related Views On News
STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)
Nov 6, 2018 | Updated on Nov 6, 2018For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
STRIDES SHASUN LTD 2017-18 Annual Report Analysis (Annual Result Update)
Oct 1, 2018 | Updated on Oct 1, 2018Here's an analysis of the annual report of STRIDES SHASUN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES SHASUN LTD. Also includes updates on the valuation of STRIDES SHASUN LTD.
STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)
Aug 10, 2018 | Updated on Aug 10, 2018For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)
Nov 30, 2018Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.
4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)
Dec 3, 2018Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.
Safety Beats Growth in 2018(Chart Of The Day)
Nov 30, 2018With the markets turning up, these are my top 7 stock picks.
Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)
Dec 5, 2018Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.
DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)
Dec 5, 2018PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.
MoreTRACK STRIDES PHARMA SCIENCE
- Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON STRIDES PHARMA SCIENCE
STRIDES PHARMA SCIENCE - TEVA PHARMA COMPARISON
COMPARE STRIDES PHARMA SCIENCE WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.